Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004484 | 0.86 | MEN1 (0.35) | TACR1JAK2JAK3PTK2JAK1 | |
| SCHEMBL4762511 | 0.83 | TACR1 (0.35) | TACR1JAK2JAK3PTK2GPR119 | |
| SCHEMBL4832492 | 0.83 | TACR1 (0.35) | TACR1JAK2JAK3PTK2 | |
| SCHEMBL4827697 | 0.78 | TACR1 (0.37) | TACR1JAK2JAK3PTK2GPR119 | |
| SCHEMBL6005121 | 0.71 | TACR1 (0.35) | TACR1JAK2JAK3PTK2ALDH1A1 | |
| SCHEMBL4814466 | 0.71 | MEN1 (0.34) | TACR1JAK2JAK3PTK2 | |
| SCHEMBL4761317 | 0.69 | NR1H2 (0.46) | TACR1ALDH1A1LMNA | |
| SCHEMBL6004024 | 0.68 | TACR1 (0.37) | TACR1JAK2JAK3PTK2JAK1 | |
| SCHEMBL6004025 | 0.66 | GRM5 (0.34) | JAK2JAK3PTK2ALDH1A1 | |
| SCHEMBL4832476 | 0.65 | USP30 (0.40) | TACR1JAK2JAK3PTK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TACR1 3601/4885JAK2 122/4885JAK3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.